Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via targeting JAK-STAT signaling of CD4+ cells

Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via targeting JAK-STAT signaling of CD4+ cells

As an inflammatory disease with a disrupted immune system, cytokine disorders in atopic dermatitis (AD) are closely related to the abnormal activation of JAK-STAT signal pathway. The critical relevance of the JAK-STAT signaling pathway to the pathogenesis of AD provides a strong rationale for JAK in...

Descripció completa

Dades bibliogràfiques
Autors principals: Shuang Chen, Caihua Li, Zeng Tu, Tao Cai, Xinying Zhang, Lei Wang, Ruoyuan Tian, Jinglan Huang, Yuxuan Gong, Xiaotong Yang, Zetong Wu, Sirong He, Wenyan He, Dan Wang
Format: Article
Idioma:English
Publicat: Frontiers Media S.A. 2024-02-01
Col·lecció:Frontiers in Pharmacology
Matèries:
atopic dermatitis
JAK/STAT
baricitinib
th2
autoimmune diseases
Accés en línia:https://www.frontiersin.org/articles/10.3389/fphar.2024.1324892/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1324892/full

Ítems similars